Human interleukin-4 receptor alpha antibodies

JP2025163009APending Publication Date: 2025-10-28ELI LILLY & CO
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2025106742
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-02
Filing Date
2025-06-24
Publication Date
2025-10-28

Smart Images

  • Figure 2025163009000015
    Figure 2025163009000015
  • Figure 2025163009000016
    Figure 2025163009000016
  • Figure 2025163009000017
    Figure 2025163009000017
Patent Text Reader

Abstract

To provide IL-4Rα antibodies for use in patients with type 2 inflammatory disorders, such as asthma, atopic dermatitis, and / or eosinophilic esophagitis (EoE), and in patients who remain resistant to treatment or are non-sustained responders to current therapies, such as dupilumab.SOLUTION: Provided are antibodies that specifically bind to human IL-4Rα and inhibit IL-4R, IL-4, and / or IL-13-mediated responses (e.g., B cell proliferation, STAT-6 phosphorylation, CD23 expression), compositions comprising such IL-4Rα antibodies, and methods of using such IL-4Rα antibodies.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Binding members for interleukin-4 receptor α(IL-4Rα)-173

    JP2011508592A

  • Screening methods for modifying polymeric Fc proteins and their functional characteristics

    JP2018510339A

  • Engineered antibody compounds and conjugates thereof

    JP2020523413A

  • Antibodies binding to human il-4r, preparation method therefor and use thereof

    WO2020048312A1